A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration

NCT03677934 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

415

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-Related Macular Degeneration

Interventions

DRUG: PDS Implant filled with 100 mg/mL Ranibizumab
DRUG: Intravitreal Injections of 10 mg/mL Ranibizumab

Sponsor

Hoffmann-La Roche